Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan

Infection and Immunity

Volumn 73, Issue 12, 2005, Pages 8256-8265

  Zhiming, Huo ^a   Sinha, Ruchi ^a   McNeela, Edel A ^b   Borrow, Ray ^c   Giemza, Rafaela ^a   Cosgrove, Catherine ^a   Heath, Paul T ^a   Mills, Kingston H G ^b   Rappuoli, Rino ^d   Griffin, George E ^a   Lewis, David J M ^a,e  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^d CHIRON VACCINES   (Italy)

^e ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CHITOSAN; DIPHTHERIA TOXIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; MENINGOCOCCUS VACCINE; MENJUGATE C; NEUTRALIZING ANTIBODY; SECRETORY IMMUNOGLOBULIN;

ADULT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; DRUG TOLERABILITY; EYE DISEASE; EYE PAIN; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; IMMUNOGLOBULIN PRODUCTION; INFECTION PREVENTION; INJECTION PAIN; MALE; MENINGOCOCCOSIS; NASAL DISCHARGE; NASAL DISCOMFORT; NASAL PRURITUS; NEISSERIA MENINGITIDIS; NORMAL HUMAN; NOSE CONGESTION; NOSE DISEASE; POWDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SERUM; SERUM BACTERICIDAL ACTIVITY; SIDE EFFECT; SNEEZING; SORE THROAT; SYMPTOM; VACCINATION; VOLUNTEER; WATERY EYE;

ADULT; ANTIBODIES, BACTERIAL; CHITOSAN; DIPHTHERIA; DIPHTHERIA TOXIN; FEMALE; HUMANS; IMMUNE SERA; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INSUFFLATION; MALE; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NASAL LAVAGE FLUID; NASAL MUCOSA; SERUM BACTERICIDAL TEST; VACCINES, CONJUGATE;

EID: 28444471597     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.73.12.8256-8265.2005     Document Type: Article

References (36)

1. Aase, A., L. M. Naess, R. H. Sandin, T. K. Herstad, F. Oftung, J. Holst, I. L. Haugen, E. A. Hoiby, and T. E. Michaelsen. 2003. Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease. Vaccine 21:2042-2051.
2. Aggerbeck, H., S. Gizurarson, J. Wantzin, and I. Heron. 1997. Intranasal booster vaccination against diphtheria and tetanus in man. Vaccine 15:307-316.
3. Andrews, N., R. Borrow, and E. Miller. 2003. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin. Diagn. Lab. Immunol. 10:780-786.
4. Aspden, T. J., J. D. Mason, N. S. Jones, J. Lowe, O. Skaugrud, and L. Illum. 1997. Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. J. Pharm. Sci. 86:509-513.
5. Bacon, A., J. Makin, P. J. Sizer, I. Jabbal-Gill, M. Hinchcliffe, L. Illum, S. Chatfield, and M. Roberts. 2000. Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect. Immun. 68:5764-5770.
6. Balmer, P., R. Borrow, and E. Miller. 2002. Impact of meningococcal C conjugate vaccine in the UK. J. Med. Microbiol. 51:717-722.
7. Baudner, B. C., M. Morandi, M. M. Giuliani, J. C. Verhoef, H. E. Junginger, P. Costantino, R. Rappuoli, and G. Del Giudice. 2004. Modulation of immune response to group C meningococcal conjugate vaccine given intranasally to mice together with the LTK63 mucosal adjuvant and the trimethyl chitosan delivery system. J. Infect. Dis. 189:828-832.
8. Bergquist, C., E.-L. Johansson, T. Lagergård, J. Holmgren, and A. Rudin. 1997. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect. Immun. 65:2676-2684.
9. Berstad, A. K., J. Holst, L. O. Froholm, I. L. Haugen, E. Wedege, F. Oftung, and B. Haneberg. 2000. A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers. J. Med. Microbiol. 49:157-163.
10. Berstad, A. K., F. Oftung, G. E. Korsvold, I. L. Haugen, L. O. Froholm, J. Hoist, and B. Haneberg. 2000. Induction of antigen-specific T cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine. Vaccine 18:2323-2330.
11. Borrow, R., P. Balmer, and E. Miller. 2005. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 23:2222-2227.
12. Bowe, F., E. C. Lavelle, E. A. McNeela, C. Hale, S. Clare, B. Arico, M. M. Giuliani, A. Rae, A. Huett, R. Rappuoli, G. Dougan, and K. H. Mills. 2004. Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin. Infect. Immun. 72:4052-4060.
13. Fries, L. F., A. D. Montemarano, C. P. Mallett, D. N. Taylor, T. L. Hale, and G. H. Lowell. 2001. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect. Immun. 69:4545-4553.
14. Goldblatt, D., R. Borrow, and E. Miller. 2002. Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults. J. Infect. Dis. 185:397-400.
15. Haneberg, B., R. Dalseg, E. Wedege, E. A. Høby, I. L. Haugen, F. Oftung, S. R. Andersen, L. M. Næss, A. Aase, T. E. Micbaelsen, and J. Holst. 1998. Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect. Immun. 66:1334-1341.
16. Hassan, J., A. Massougbodji, J. P. Chippaux, B. Massit, and R. Josse. 1998. Meningococcal immunisation and protection from epidemics. Lancet 352: 407-408.
17. Huo, Z. M., J. Miles, P. G. Riches, and T. Harris. 2002. Limitations of Pneumovax as a detection antigen in the measurement of serotype-speciflc antibodies by enzyme-linked immunosorbent assay. Ann. Clin. Biochem. 39:398-403.
18. Hutchins, W, A., G. M. Carlone, and M. A. Westerink. 1999. Elderly immune response to a TI-2 antigen: heavy and light chain use and bactericidal activity to Neisseria meningitidis serogroup C polysaccharide. J. Infect. Dis. 179: 1433-1440.
19. Joseph, H., P. Balmer, M. Bybel, T. Papa, R. Ryall, and R. Borrow. 2004. Assignment of Neisseria meningitidis serogroups A, C, W135, and Y anticapsular total immunoglobulin G (IgG), IgG1, and IgG2 concentrations to reference sera. Clin. Diagn. Lab. Immunol. 11:1-5.
20. Katial, R. K., B. L. Brandt, E. E. Moran, S. Marks, V. Agnello, and W. D. Zollinger. 2002. Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine. Infect. Immun. 70: 702-707.
21. Krieg, C., R. Maier, and A. Meyerhans. 2004. Gut-homing (alpha(4)beta(7)(+)) Th1 memory responses after inactivated poliovirus immunization in poliovirus orally pre-immunized donors. J. Gen. Virol. 85:1571-1579.
22. Kuper, C. F., P. J. Koornstra, D. M. Hameleers, J. Biewenga, B. J. Spit, A. M. Duijvestijn, P. J. van Breda Vriesman, and T. Sminia. 1992. The role of nasopharyngeal lymphoid tissue. Immunol. Today 13:219-224.
23. Larbig, M., E. Mansouri, J. Freihorst, B. Tummler, G. Kohler, H. Domdey, B. Knapp, K. D. Hungerer, E. Hundt, J. Gabelsberger, and B. U. von Specht. 2001. Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Vaccine 19:2291-2297.
24. McNeela, E. A., D. O'Connor, I. Jabbal-Gill, L. Illum, S. S. Davis, M. Pizza, S. Peppoloni, R. Rappuoli, and K. H. Mills. 2000. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine 19:1188-1198.
25. Mills, K. H. G., C. Cosgrove, E. A. McNeela, A. Sexton, R. Giemza, I. Jabbal-Gill, A. Church, W. Lin, L. Illum, A. Podda, R. Rappuoli, M. Pizza, G. E. Griffin, and D. J. M. Lewis. 2003. Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin A. Infect. Immun. 71:726-732.
26. Miyamura, K., S. Nisbio, A. Ito, R. Murata, and R. Kono. 1974. Micro cell culture method for determination of diphtheria toxin and antitoxin titres using VERO cells. I. Studies on factors affecting the toxin and antitoxin titration. J. Biol. Stand. 2:189-201.
27. Naess, L. M., T. Aarvak, A. Aase, F. Oftung, E. A. Hoiby, R. Sandin, and T. E. Michaelsen. 1999. Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine. Vaccine 17:754-764.
28. Nakhla, I., R. W. Frenck, Jr., N. A. Teleb, S. E. Oun, Y. Sultan, H. Mansour, and F. Mahoney. 2005. The changing epidemiology of meningococcal meningitis after introduction of bivalent A/C polysaccharide vaccine into school-based vaccination programs in Egypt. Vaccine 23:3288-3293.
29. Perera, V. Y., and M. J. Corbel. 1990. Human antibody response to fragments A and B of diphtheria toxin and a synthetic peptide of amino acid residues 141-157 of fragment A. Epidemiol. Infect. 105:457-468.
30. Quiding-Järbrink, M., G. Granström, I. Nordström, J. Holmgren, and C. Czerkinsky. 1995. Induction of compartmentalized B-cell responses in human tonsils. Infect. Immun. 63:853-857.
31. Rudin, A., E.-L. Johansson, C. Bergquist, and J. Holmgren. 1998. Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans. Infect. Immun. 66: 3390-3396.
32. Sminia, T., and G. Kraal. 1999. Nasal associated lymphoid tissue, p. 357-364. In P. Ogra, J. Mestecky, M. Lamm, W. Strober, J. Bienenstock, and J. McGhee (ed.), Mucosal immunology, 2nd ed. Academic Press, San Diego, Calif.
33. Soane, R. J., M. Frier, A. C. Perkins, N. S. Jones, S. S. Davis, and L. Illum. 1999. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int. J. Pharm. 178:55-65.
34. Tarkowski, A., C. Lue, Z. Moldoveanu, H. Kiyono, J. R. McGhee, and J. Mestecky. 1990. Immunization of humans with polysaccharide vaccines induces systemic, predominantly polymeric IgA2-subcIass antibody responses. J. Immunol. 144:3770-3778.
35. Tikhomirov, E., M. Santamaria, and K. Esteves. 1997. Meningococcal disease: public health burden and control. World Health Stat. Q. 50:170-177.
36. Trotter, C. L., N. J. Andrews, E. B. Kaczmarski, E. Miller, and M. E. Ramsay. 2004. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364:365-367.